Inhibrx Biosciences Inc INBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Inhibrx Announces Participation in Upcoming Scientific Conferences
-
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
-
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
-
Inhibrx Reports Second Quarter 2026 Financial Results
-
Inhibrx Shares Fall After Expanding Loan Agreement to $500 Million
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 14.72M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 110
- Website
- https://www.inhibrx.com
Valuation
|
Metric
|
INBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
INBX
Financial Strength
|
Metric
|
INBX
|
|---|---|
Quick Ratio | 4.76 |
Current Ratio | 5.07 |
Interest Coverage | −8.22 |
Quick Ratio
INBX
Profitability
|
Metric
|
INBX
|
|---|---|
Return on Assets (Normalized) | −73.74% |
Return on Equity (Normalized) | −1,637.51% |
Return on Invested Capital (Normalized) | −83.64% |
Return on Assets
INBX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|lV^<^&s | LOCK|nCMz | $127B | |||
| Moderna Inc
MRNA
| LOCK|B!WF&W% | LOCK|R%$ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#vJh<> | LOCK|>dSg | $81B | |||
| argenx SE ADR
ARGX
| LOCK|&YvS&$$ | LOCK|^<Z | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^^nMJj | LOCK|>h | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%#?m#$$ | LOCK|<zH> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|qzjn>NG% | LOCK|YX@!< | $27B | |||
| Incyte Corp
INCY
| LOCK|XrB%RK# | LOCK|$J | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|TwgNJ&@ | LOCK|y< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|dHSYGlp | LOCK|!x | $14B |
United States